Latest Embryonics News
Mar 14, 2021
AI can now pick the best embryo to implant for IVF While the bioscience aspects of IVF have advanced, it lags behind other healthcare verticals in the use of data science, says Fairtility CEO. Photo by Alicia Petresc on Unsplash Louise Brown, the world’s first “test tube” baby, was born in 1978 through in vitro fertilization (IVF). In IVF, sperm and egg meet outside the body and the best resulting embryo is implanted into the womb in hopes of a healthy pregnancy. “There have been so many advancements in the bioscience aspects of IVF since then, but it lags behind other healthcare verticals big time as far as data science — and there is a lot of data that is not being used,” Eran Eshed, CEO and cofounder of Fairtility , tells ISRAEL21c. “Today, the process of assisted reproductive technology is based on experience and subjective judgment. The outcomes are not very impressive – it takes an average of three IVF cycles per patient to take a baby home,” says Eshed. While IVF in Israel is free for two pregnancies, in most countries the treatment is expensive – an average of $20,000 per cycle in the United States. Three tries is beyond the budget of most prospective parents. Furthermore, IVF involves stressful and painful procedures. Founded in Tel Aviv in 2019, Fairtility is coming out of stealth mode with its technology to improve the critical IVF stage of choosing the most viable embryo to implant. Embryo ranking, says Eshed, is where the process often fails. “The embryologist ranks anywhere between two and 15 fertilized eggs based on their potential to create a healthy pregnancy, and decides which one to transfer to the mom,” he explains. “It’s a tedious and challenging task considering the complexity of the images and significance of nuances that are easily missed by the human eye.” Fairtility applies artificial intelligence (AI) and computer vision to the task. Its implantation prediction accuracy exceeds 90 percent in tests. The technology, now undergoing pilots in Israel and several other countries, is “trained” using plentiful existing datasets and embryo images at different developmental stages. “Humans have limitations that computers don’t. Our product far exceeds the accuracy of human embryologists and automates the process to make it more efficient,” says Eshed, whose previous company, semiconductor maker Altair, was acquired by Sony in 2016 . “Our objective is to shorten time to pregnancy and reduce all the associated costs, pain and stress,” he says. Eshed’s cofounders are CMO Dr. Assaf Ben-Meir , head of the IVF Center at Hadassah Ein Kerem Medical Center in Jerusalem; and CTO Itay Erlich, formerly senior algorithm developer at OrCam. Fairtility is preparing CE (Europe) and FDA (US) submissions and expects to go commercial this year. “The percentage of patients that get to do IVF is less than 1% of those seeking it. There’s a huge supply-demand gap,” says Eshel. “In the US, 7 million people suffer from infertility, but there are only 350,000 IVF cycles annually. That means something could be done a lot better.” Embryonics and AIVF Fairtility is not the only Israeli company aiming to improve IVF success with the help of artificially intelligent embryo ranking. Embryonics and AIVF are also developing data-based AI solutions to boost the capabilities of human embryologists. Founded in 2018 in Haifa, Embryonics reports that its Ubar technology, using a technique called geometric deep learning, is undergoing clinical trials in Ukraine. US clinical trials are to begin this year. Ubar is expected to improve the overall success rate of the IVF process by 10% on average. The technology also could be used to personalize the hormone treatments preceding IVF, and to select which eggs to preserve, according to CEO Dr. Yael Gold-Zamir. Embryonics’ team includes, among others, bioinformatics David Silver, who formerly worked at Apple and Intel; and scientific adviser Prof. Alex Bronstein, heads of the Center for Intelligent Systems at the Technion-Israel Institute of Technology. AIVF, headed and cofounded by clinical embryologist and biostatistician Daniella Gilboa, has clinical trials underway in Israel, Europe and the United States. It plans to launch commercially in 2021. AIVF’s ML technique involves creating time-lapse videos of developing embryos in an incubator. Over five days, the video shows the milestones of embryo development. “By analyzing the video, you could dig out so many milestones and so many features the human eye cannot even detect,” Gilboa told IEEE magazine in December. “Basically you train an algorithm on successful embryos, and you teach the algorithm what are successful embryos.” AIVF’s cofounder and chief medical officer, Dr. Daniel Seidman , co-directs the IVF unit at Assuta Medical Center in Tel Aviv. The company also has a “chief behavioral officer,” the noted Israeli behavioral economist Prof. Dan Ariely of Duke University.